Enlivex Therapeutics Ltd

Contributing Author

Recent Articles by Enlivex Therapeutics Ltd

Feb-10	Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange ENLV GlobeNewswire
Jan-26	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange ENLV +8.33% GlobeNewswire
Jan-23	Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq ENLV GlobeNewswire
Jan-07	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin, a Leading Cryptocurrency Exchange ENLV GlobeNewswire
Dec-04	Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development ENLV +6.42% GlobeNewswire
Nov-26	Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement ENLV -8.16% GlobeNewswire
Nov-24	Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board ENLV +13.74% GlobeNewswire
Nov-24	Enlivex Announces Positive 6-Month Topline Data -Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis ENLV +13.74% GlobeNewswire
Oct-28	Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 ENLV GlobeNewswire
Sep-29	D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program ENLV GlobeNewswire
Sep-11	Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra Results ENLV +5.42% GlobeNewswire
Sep-09	Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis ENLV GlobeNewswire
Aug-18	Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis ENLV -31.32% GlobeNewswire
Aug-14	Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar ENLV +14.10% GlobeNewswire
Jul-28	Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data ENLV +12.30% GlobeNewswire
Jun-10	Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology ENLV GlobeNewswire
May-20	Enlivex Selected to Present at Israeli BioMed 2025 Conference ENLV GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.